Short Introduction of Sublingual Drug Delivery System
Corresponding Author(s) : Asha Kumari
ashamahtoa@gmail.com
International Journal of Allied Medical Sciences and Clinical Research,
Vol. 2021 No. 9 (4): 2021 Volume - 9 Issue - 4
Abstract
Onset of action is needed in the case of some acute diseases. Hence the Sublingual drug delivery can be best promising route of administration for a faster and direct absorption of drug into systemic circulation. The most permeable region for a drug absorption in buccal cavity is the Sublingual region. Absorption of a drug through the sublingual blood vessels bypasses the hepatic first-pass metabolism that makes better bioavailability along good patient compliance. Such sublingual approaches present numerous pharmaceutical and patient needs those are enhanced life-cycle management to suitable dosing for children as well as elderly along psychiatric patients with dysphagia. This review is to give a brief and complete overview of sublingual technologies along new and old approaches.
Keywords
Sublingual
permeability
bioavailability
first pass metabolism
dysphagia
1.
Dr. Mayank Bansal, Jitendra Kumar, Sunil Sain, Asha Kumari. Short Introduction of Sublingual Drug Delivery System. Int. J. of Allied Med. Sci. and Clin. Res. [Internet]. 2021 Nov. 17 [cited 2026 May 2];2021(9):652-6. Available from: https://ijamscr.com/ijamscr/article/view/1101
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
References
-
1. Aburahma MH, El-Laithy HM, Hamza YE. Preparation and In Vitro/ In Vivo Characteriza- tion of porous sublingual tablets containing ternary kneaded solid system of Vinpocetine with ?-Cyclodextrin and hydroxy acid. Sci Pharm. 2010; 78; 363-379.
2. Al-Ghananeem AM, Malkawi AH, Crooks PA. Scopolamine sublingual spray: an alternative route of delivery for the treatment of motion sickness. Drug Dev Ind Pharm. 2007; 33(5): 577–582.
3. Boer D, et al. Drug absorption by sublingual and rectal routes. Brit J Anaesth. 1984; 56: 69-82.
4. Bolourtchian N, Hadidi N, Foroutan SM, Sha- faghi B. Development and optimization of sub- lingual tablet formulation for Physostigmine Salicylate. Acta Pharm. 2009; 59: 301-312.
5. Bolourtchian N, Hadidi N, Foroutan SM, Sha- faghi B. Formulation and optimization of cap- topril sublingual tablet using D-Optimal de- sign. Iranian J Pharm Res. 2008; 7(4): 259-267.
6. Bottenbrg P, Cleymact R, dc Muynck C, Rey- mon JP, Coomans D, Michotte Y, et al. Devel- opment and testing of fluoride containing slow release tablets for oral use. J Pharm Pharmacol. 1991; 43: 457-464.
7. Centkowska K, Sznitowska M. Comparison of sublingual tablets with nitroglycerin com- plexed with ?-Cyclodextrin or titrated with crosspovidone - Technological approach. Acta Pol Pharm- Drug Res. 2008; 65(5): 585-589.
8. Ghosh TK, Chatterjee DJ, Pfister WR. Quick dissolving oral dosage forms: Scientific and regulatory considerations from a clinical Pharmacology and Biopharmaceutical perspective, In: Ghosh TK, Pfister WR, editors, Drug Delivery to the Oral Cavity Molecules to Market, NY, USA; CRC Press: 3537-3567 (2005).
9. Haegeli L, Brunner-La Rocca HP, Wenk M, Pfisterer M, Drewe J, Krahenbuhl S. Sublingual administration of furosemide: new application of an old drug. Brit J Clin Pharmcol. 2007; 64(6): 804-809.
10. John DN, Fort S, Lewis MJ, Luscombe DK. Pharmacokinetics and Pharmacodynamics of Verapamil following sublingual and oral ad- ministration to healthy volunteers. Br J Clin Pham 1992; 33: 623-627.
11. Kurosaki Y, Takatori T, Nishimura H, Na- kayama T, Kimura T. Regional variation in oral mucosal drug absorption permeability and degree of keratinization in hamster oral cavity. Pharm Res. 1991; 8: 1297-1301.
12. Lipinski CA, Lombardo F, Dominy BW, Fee- ney PJ. Experimental and computational approaches to estimate solubility and permeabili- ty in drug discovery and development set- tings. Adv Drug Del Rev. 1997; 23: 3-25.
13. McElnay JC, Al-Furaih TA, Hughes CM, Scott MG, Elborn JS, Nicholls DP. The effect of pH on the buccal and sublingual absorption of captopril. Eur J Clin Pharmacol. 1995; 48(5): 373-379.
14. Nafee NA, Boraie NA, Ismail FA, Mortada IM. Design and characterization of mucoadhesive buccal patches containing cetylpyridinium chloride. Acta Pharm. 2003; 53: 199-212.
15. Narang N, Sharma J. Sublingual mucosa as a route for systemic drug delivery. Int J Pharm Pharm Sci. 2011; 3(2): 18-22.
16. Peh KK, Wong CF. Polymeric films as vehicles for buccal delivery; swelling, mechanical, and films of glipizide. Indian J Pharm Sci. 2008; 70:43-48.
17. Price TM, Blauer KL, Hansen M, Stanczyk F, Lobo R, Bates GW. Single - dose Pharmacoki- netics of sublingual versus oral administration of micronized 17 beta – estradiol. Obstet Gyne- col. 1997; 89: 340-345.
18. Richman MD, Fox D, Shangraw RF. Prepara- tion and stability of glyceryl trinitrate sublin- gual tablets prepared by direct compression. J Pharm Sci. 1965; 54(3): 447-451.
19. Shojaie AH. Buccal mucosa as a route for sys- temic drug delivery: A review. J Pharm Pharm Sci. 1998; 1(1): 15-30.
20. Sheeba FR, Acharya GD, Rameshwari S, Jeya AJ. Formulation and evaluation of nifedipine sublingual tablets. Asian J Pharm Clin Res. 2009; 2(3): 44-48.
21. Thosar M M. Intra oral sprays -An overview. Int J Pharm Life Sci. 2011; 2(11):1235-1246.
22. Walton RP. Absorption of drugs through the oral mucosa III Fat -water solubility co- efficient of alkaloids. Proc Soc Exp Bio Med. 1935; 32: 1488-1493.
References
1. Aburahma MH, El-Laithy HM, Hamza YE. Preparation and In Vitro/ In Vivo Characteriza- tion of porous sublingual tablets containing ternary kneaded solid system of Vinpocetine with ?-Cyclodextrin and hydroxy acid. Sci Pharm. 2010; 78; 363-379.
2. Al-Ghananeem AM, Malkawi AH, Crooks PA. Scopolamine sublingual spray: an alternative route of delivery for the treatment of motion sickness. Drug Dev Ind Pharm. 2007; 33(5): 577–582.
3. Boer D, et al. Drug absorption by sublingual and rectal routes. Brit J Anaesth. 1984; 56: 69-82.
4. Bolourtchian N, Hadidi N, Foroutan SM, Sha- faghi B. Development and optimization of sub- lingual tablet formulation for Physostigmine Salicylate. Acta Pharm. 2009; 59: 301-312.
5. Bolourtchian N, Hadidi N, Foroutan SM, Sha- faghi B. Formulation and optimization of cap- topril sublingual tablet using D-Optimal de- sign. Iranian J Pharm Res. 2008; 7(4): 259-267.
6. Bottenbrg P, Cleymact R, dc Muynck C, Rey- mon JP, Coomans D, Michotte Y, et al. Devel- opment and testing of fluoride containing slow release tablets for oral use. J Pharm Pharmacol. 1991; 43: 457-464.
7. Centkowska K, Sznitowska M. Comparison of sublingual tablets with nitroglycerin com- plexed with ?-Cyclodextrin or titrated with crosspovidone - Technological approach. Acta Pol Pharm- Drug Res. 2008; 65(5): 585-589.
8. Ghosh TK, Chatterjee DJ, Pfister WR. Quick dissolving oral dosage forms: Scientific and regulatory considerations from a clinical Pharmacology and Biopharmaceutical perspective, In: Ghosh TK, Pfister WR, editors, Drug Delivery to the Oral Cavity Molecules to Market, NY, USA; CRC Press: 3537-3567 (2005).
9. Haegeli L, Brunner-La Rocca HP, Wenk M, Pfisterer M, Drewe J, Krahenbuhl S. Sublingual administration of furosemide: new application of an old drug. Brit J Clin Pharmcol. 2007; 64(6): 804-809.
10. John DN, Fort S, Lewis MJ, Luscombe DK. Pharmacokinetics and Pharmacodynamics of Verapamil following sublingual and oral ad- ministration to healthy volunteers. Br J Clin Pham 1992; 33: 623-627.
11. Kurosaki Y, Takatori T, Nishimura H, Na- kayama T, Kimura T. Regional variation in oral mucosal drug absorption permeability and degree of keratinization in hamster oral cavity. Pharm Res. 1991; 8: 1297-1301.
12. Lipinski CA, Lombardo F, Dominy BW, Fee- ney PJ. Experimental and computational approaches to estimate solubility and permeabili- ty in drug discovery and development set- tings. Adv Drug Del Rev. 1997; 23: 3-25.
13. McElnay JC, Al-Furaih TA, Hughes CM, Scott MG, Elborn JS, Nicholls DP. The effect of pH on the buccal and sublingual absorption of captopril. Eur J Clin Pharmacol. 1995; 48(5): 373-379.
14. Nafee NA, Boraie NA, Ismail FA, Mortada IM. Design and characterization of mucoadhesive buccal patches containing cetylpyridinium chloride. Acta Pharm. 2003; 53: 199-212.
15. Narang N, Sharma J. Sublingual mucosa as a route for systemic drug delivery. Int J Pharm Pharm Sci. 2011; 3(2): 18-22.
16. Peh KK, Wong CF. Polymeric films as vehicles for buccal delivery; swelling, mechanical, and films of glipizide. Indian J Pharm Sci. 2008; 70:43-48.
17. Price TM, Blauer KL, Hansen M, Stanczyk F, Lobo R, Bates GW. Single - dose Pharmacoki- netics of sublingual versus oral administration of micronized 17 beta – estradiol. Obstet Gyne- col. 1997; 89: 340-345.
18. Richman MD, Fox D, Shangraw RF. Prepara- tion and stability of glyceryl trinitrate sublin- gual tablets prepared by direct compression. J Pharm Sci. 1965; 54(3): 447-451.
19. Shojaie AH. Buccal mucosa as a route for sys- temic drug delivery: A review. J Pharm Pharm Sci. 1998; 1(1): 15-30.
20. Sheeba FR, Acharya GD, Rameshwari S, Jeya AJ. Formulation and evaluation of nifedipine sublingual tablets. Asian J Pharm Clin Res. 2009; 2(3): 44-48.
21. Thosar M M. Intra oral sprays -An overview. Int J Pharm Life Sci. 2011; 2(11):1235-1246.
22. Walton RP. Absorption of drugs through the oral mucosa III Fat -water solubility co- efficient of alkaloids. Proc Soc Exp Bio Med. 1935; 32: 1488-1493.
2. Al-Ghananeem AM, Malkawi AH, Crooks PA. Scopolamine sublingual spray: an alternative route of delivery for the treatment of motion sickness. Drug Dev Ind Pharm. 2007; 33(5): 577–582.
3. Boer D, et al. Drug absorption by sublingual and rectal routes. Brit J Anaesth. 1984; 56: 69-82.
4. Bolourtchian N, Hadidi N, Foroutan SM, Sha- faghi B. Development and optimization of sub- lingual tablet formulation for Physostigmine Salicylate. Acta Pharm. 2009; 59: 301-312.
5. Bolourtchian N, Hadidi N, Foroutan SM, Sha- faghi B. Formulation and optimization of cap- topril sublingual tablet using D-Optimal de- sign. Iranian J Pharm Res. 2008; 7(4): 259-267.
6. Bottenbrg P, Cleymact R, dc Muynck C, Rey- mon JP, Coomans D, Michotte Y, et al. Devel- opment and testing of fluoride containing slow release tablets for oral use. J Pharm Pharmacol. 1991; 43: 457-464.
7. Centkowska K, Sznitowska M. Comparison of sublingual tablets with nitroglycerin com- plexed with ?-Cyclodextrin or titrated with crosspovidone - Technological approach. Acta Pol Pharm- Drug Res. 2008; 65(5): 585-589.
8. Ghosh TK, Chatterjee DJ, Pfister WR. Quick dissolving oral dosage forms: Scientific and regulatory considerations from a clinical Pharmacology and Biopharmaceutical perspective, In: Ghosh TK, Pfister WR, editors, Drug Delivery to the Oral Cavity Molecules to Market, NY, USA; CRC Press: 3537-3567 (2005).
9. Haegeli L, Brunner-La Rocca HP, Wenk M, Pfisterer M, Drewe J, Krahenbuhl S. Sublingual administration of furosemide: new application of an old drug. Brit J Clin Pharmcol. 2007; 64(6): 804-809.
10. John DN, Fort S, Lewis MJ, Luscombe DK. Pharmacokinetics and Pharmacodynamics of Verapamil following sublingual and oral ad- ministration to healthy volunteers. Br J Clin Pham 1992; 33: 623-627.
11. Kurosaki Y, Takatori T, Nishimura H, Na- kayama T, Kimura T. Regional variation in oral mucosal drug absorption permeability and degree of keratinization in hamster oral cavity. Pharm Res. 1991; 8: 1297-1301.
12. Lipinski CA, Lombardo F, Dominy BW, Fee- ney PJ. Experimental and computational approaches to estimate solubility and permeabili- ty in drug discovery and development set- tings. Adv Drug Del Rev. 1997; 23: 3-25.
13. McElnay JC, Al-Furaih TA, Hughes CM, Scott MG, Elborn JS, Nicholls DP. The effect of pH on the buccal and sublingual absorption of captopril. Eur J Clin Pharmacol. 1995; 48(5): 373-379.
14. Nafee NA, Boraie NA, Ismail FA, Mortada IM. Design and characterization of mucoadhesive buccal patches containing cetylpyridinium chloride. Acta Pharm. 2003; 53: 199-212.
15. Narang N, Sharma J. Sublingual mucosa as a route for systemic drug delivery. Int J Pharm Pharm Sci. 2011; 3(2): 18-22.
16. Peh KK, Wong CF. Polymeric films as vehicles for buccal delivery; swelling, mechanical, and films of glipizide. Indian J Pharm Sci. 2008; 70:43-48.
17. Price TM, Blauer KL, Hansen M, Stanczyk F, Lobo R, Bates GW. Single - dose Pharmacoki- netics of sublingual versus oral administration of micronized 17 beta – estradiol. Obstet Gyne- col. 1997; 89: 340-345.
18. Richman MD, Fox D, Shangraw RF. Prepara- tion and stability of glyceryl trinitrate sublin- gual tablets prepared by direct compression. J Pharm Sci. 1965; 54(3): 447-451.
19. Shojaie AH. Buccal mucosa as a route for sys- temic drug delivery: A review. J Pharm Pharm Sci. 1998; 1(1): 15-30.
20. Sheeba FR, Acharya GD, Rameshwari S, Jeya AJ. Formulation and evaluation of nifedipine sublingual tablets. Asian J Pharm Clin Res. 2009; 2(3): 44-48.
21. Thosar M M. Intra oral sprays -An overview. Int J Pharm Life Sci. 2011; 2(11):1235-1246.
22. Walton RP. Absorption of drugs through the oral mucosa III Fat -water solubility co- efficient of alkaloids. Proc Soc Exp Bio Med. 1935; 32: 1488-1493.